Asceneuron Expands Scientific Advisory Board with World Leading Experts in Neurodegenerative Diseases

Posted on by

Significant appointments of industry and academic experts to support Phase II development of ASN51 in Alzheimer’s disease LAUSANNE, Switzerland and SAN FRANCISCO, March 6, 2024 /PRNewswire/ — Asceneuron SA, a clinical stage biotech company dedicated to targeting the root causes of…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.